Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Repair Biotechnologies Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with the company's filings. This 1 pending office action defines the current workload for the entity's intellectual property prosecution.
The examination process involves 1 distinct examiner and 1 distinct art unit. IANNUZO, NATALIE NMN is the busiest examiner for the portfolio, with 1 pending office action under review. This indicates that the totality of the company's active patent office interactions is managed by this single examiner.
Practitioners should focus on the specific requirements of 1 distinct art unit and the individual tendencies of IANNUZO, NATALIE NMN. Since there is 1 pending office action, the strategy is concentrated. The consolidation of the active workload with 1 distinct examiner simplifies the coordination of the prosecution process. Success in this single track will determine the immediate status of the company's intellectual property in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 50d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 1653 | §102§103 | Final Rejection | 50d overdue | Pending | Jun 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial